FedCircuitBlog

• Showdown Looms on Cost Accounting Standards – Boeing can challenge a Federal Acquisition Regulation provision regarding Cost Accounting Standards thanks to a recent Federal Circuit decision.
• A $75 Million Drug Sale Lands Teva a $235 Million Penalty – The Federal Circuit awarded $235 million to Glaxosmithkline for Teva’s sale of a generic version of a Glaxosmithkline heart medicine.

Here’s the latest.

• Qualcomm Urges Fed Circuit to Keep PTAB Win Against Apple – Arguing that Apple is now trying to “manufacture a legal issue,” Qualcomm maintains that the PTAB correctly upheld its patent on a touch-screen function that allows users to toggle between multiple windows.
• CAFC Affirms Sanctions Entered Against Overly Litigious Doctors – Last week, the Court of Appeals for the Federal Circuit (CAFC) affirmed a district court decision in Kahn v. Hemisphere Inc, which involved an action for patent infringement regarding an arteriovenous shunt.
• Government Reliance on Waiver Argument to Keep Price Adjustment Windfall Fails – In articulating limits to the government’s ability to rely on the waiver doctrine to enforce Federal Acquisition Regulation (“FAR”) provisions of questionable legality, the Federal Circuit in effect challenges the government’s approach to measuring the impact of cost accounting practices changes.

Here’s the latest.

This morning the Federal Circuit issued one precedential opinion in a government contracts case. Here is the introduction to the opinion.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights an amicus brief urging the Supreme Court to hear a case challenging the retroactive application of inter partes reviews, a Federal Circuit decision on reprisal claims under the Whistleblower Protection Act, a lawsuit brought by Boeing to protect data in federal contracts, and a Federal Circuit decision allowing attorney fees following a settlement between parties.